Lymphoma clinical trials in Utah

31 actively recruiting lymphoma trials at 6 sites across Utah.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 3 Recruiting NIH

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05675410

Sites in Utah:

Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
Primary Children's Hospital — Salt Lake City, Utah

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This st…

Sponsor: Genmab

NCT ID: NCT06191744

Sites in Utah:

Intermountain Healthcare LDS Hospital /ID# 259759 — Salt Lake City, Utah

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be m…

Sponsor: Regeneron Pharmaceuticals

NCT ID: NCT06091254

Sites in Utah:

Huntsman Cancer Institute - Oncology Division — Salt Lake City, Utah

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04546399

Sites in Utah:

Primary Children's Hospital — Salt Lake City, Utah

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…

Sponsor: American Society of Clinical Oncology

NCT ID: NCT02693535

Sites in Utah:

Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center — Cedar City, Utah
Intermountain Healthcare — Salt Lake City, Utah
Dixie Regional Medical Center-River Road Campus — St. George, Utah

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Academic/Other

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…

Sponsor: PedAL BCU, LLC

NCT ID: NCT04726241

Sites in Utah:

Primary Children's Hospital — Salt Lake City, Utah

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017…

Sponsor: Juno Therapeutics, a Subsidiary of Celgene

NCT ID: NCT03331198

Sites in Utah:

Huntsman Cancer Institute — Salt Lake City, Utah
Local Institution - 0028 — Salt Lake City, Utah

View on ClinicalTrials.gov →

Phase 2 Recruiting Industry

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still ma…

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT06890884

Sites in Utah:

Intermountain Medical Center ( Site 0182) — Murray, Utah
Intermountain Healthcare - St. George ( Site 0203) — St. George, Utah

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Network

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…

Sponsor: Children's Oncology Group

NCT ID: NCT04870944

Sites in Utah:

Primary Children's Hospital — Salt Lake City, Utah

View on ClinicalTrials.gov →

Phase 2 Recruiting Industry

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse ev…

Sponsor: Janssen Research & Development, LLC

NCT ID: NCT05963074

Sites in Utah:

Community Cancer Trials of Utah — Ogden, Utah

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD…

Sponsor: Lyell Immunopharma, Inc.

NCT ID: NCT05826535

Sites in Utah:

Huntsman Cancer Institute — Salt Lake City, Utah
Intermountain Healthcare — Salt Lake City, Utah

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the firs…

Sponsor: Etan Orgel

NCT ID: NCT05082519

Sites in Utah:

Primary Children's Hospital — Salt Lake City, Utah

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancie…

Sponsor: BeOne Medicines

NCT ID: NCT06634589

Sites in Utah:

Huntsman Cancer Institute — Salt Lake City, Utah

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT06395103

Sites in Utah:

Intermountain - Primary Children's Hospital ( Site 1014) — Salt Lake City, Utah

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and to character…

Sponsor: Debiopharm International SA

NCT ID: NCT05765812

Sites in Utah:

Huntsman Cancer Institute — Salt Lake City, Utah

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

This phase II trial tests how well zanubrutinib and lisocabtagene maraleucel (liso-cel) work together in treating patients with Richter's syndrome that has come back (recurrent) or does not respond to treatment (refractory). Richter's synd…

Sponsor: Aseel Alsouqi

NCT ID: NCT05873712

Sites in Utah:

Huntsman Cancer Institute — Salt Lake City, Utah

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)

The purpose of this clinical trial is to learn if the drugs Pirtobrutinib and Rituximab are effective for the treatment of newly diagnosed marginal zone lymphoma.

Sponsor: University of Utah

NCT ID: NCT06390956

Sites in Utah:

Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

The goal of this clinical trial is to study the combination of nivolumab and axatilimab in patients with relapsed/refractory classical Hodgkin Lymphoma. This study will mainly look at if the combination works as expected.

Sponsor: University of Utah

NCT ID: NCT05723055

Sites in Utah:

Huntsman Cancer Institute at the University of Utah — Salt Lake City, Utah

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)

The purpose of this clinical trial is to learn if the study treatment Loncastuximab tesirine and Rituximab is safe and efficient before standard of care chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed or refracto…

Sponsor: University of Utah

NCT ID: NCT06788964

Sites in Utah:

Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah

View on ClinicalTrials.gov →

Phase 1 Recruiting NIH

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

This phase I trial tests the safety, side effects, best dose and effectiveness of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma. Lenalid…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04609046

Sites in Utah:

Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.

Sponsor: Caribou Biosciences, Inc.

NCT ID: NCT04637763

Sites in Utah:

Huntsman Cancer Institute at the University of Utah — Salt Lake City, Utah

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or rec…

Sponsor: ADC Therapeutics S.A.

NCT ID: NCT04970901

Sites in Utah:

Huntsman Cancer Institute — Salt Lake City, Utah

View on ClinicalTrials.gov →

Phase 1 Recruiting Academic/Other

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

The purpose of this study is to find out whether the combination of epcoritamab and ibrutinib is a safe treatment approach that causes few or mild side effects in people with relapsed/refractory primary central nervous system lymphoma (PCN…

Sponsor: Memorial Sloan Kettering Cancer Center

NCT ID: NCT07082868

Sites in Utah:

University of Utah — Salt Lake City, Utah

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up…

Sponsor: Newave Pharmaceutical Inc

NCT ID: NCT04771572

Sites in Utah:

University of Utah — Salt Lake City, Utah

View on ClinicalTrials.gov →

Phase 1 Recruiting Network

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has com…

Sponsor: AIDS Malignancy Consortium

NCT ID: NCT05077527

Sites in Utah:

Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah

View on ClinicalTrials.gov →

Showing 25 of 31 trials with sites in Utah. See all lymphoma trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20